Tilvestamab

替卫妥单抗

Report date: 2024/10/31 20:00:05

Base Information

Drug NameTilvestamab

Drug Alias NameBGB-149

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionAXL receptor tyrosine kinase inhibitors

TargetsAXL receptor tyrosine kinase

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingaporeNorwayUnited Kingdom +[4]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBergenbio

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesBergenbio Asa

Active IndicationsN/A

Inactive IndicationsOvarian Neoplasms

ATC CodeN/A